Ask AI
Adjuvant Olaparib in HER2- EBC

CE / CME

Germline BRCA Testing and Targeting With Adjuvant Olaparib in HER2- EBC

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: May 17, 2022

Expiration: May 16, 2023

Activity

Progress
1
Course Completed

In this module, Yara Abdou, MD, discusses adjuvant therapy with olaparib for patients with germline BRCA (gBRCA) mutations and HER2-negative, high-risk early breast cancer (EBC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?
In your current practice, which adjuvant therapy would you consider for this patient?